Diabetic kidney disease has a high global disease burden and substantially increases the
risk of kidney failure and cardiovascular events. Despite treatment, there is substantial …

Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent liver disease
in the world, yet there are still no approved pharmacological therapies to prevent or treat this …

Nearly half of all adults with type 2 diabetes mellitus (T2DM) live in India and China. These
populations have an underlying predisposition to deficient insulin secretion, which has a key …

Background Dapagliflozin reduces the risk of kidney failure and heart failure in patients with
chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney …

Vascular complications of diabetes pose a severe threat to human health. Prevention and
treatment protocols based on a single vascular complication are no longer suitable for the …

Background Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist,
reduced albuminuria in short-term trials involving patients with chronic kidney disease …

Immunoglobulin A (IgA) nephropathy is a common form of glomerulonephritis, which despite
use of renin-angiotensin-aldosterone-system blockers and immunosuppressants, often …

Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal
proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic …

After the publication of the revised edition, therapeutic drugs described in “Future Treatment”
were approved and important evidence for pharmacologic therapy and nonpharmacologic …

Type 2 diabetes mellitus (T2DM) is a chronic, complex metabolic disease characterized by
chronic hyperglycemia causing from insufficient insulin signaling because of insulin …